TrackPaw secures €2.3M to revolutionise preclinical research with AI-powered monitoring
TrackPaw Scientific has closed a €2.3M seed funding round co-led by FSG Fund II and Industrifonden, two leading investors in life science and technology. The round also includes €0.5M from existing shareholders. The funding will enable TrackPaw to advance from its current beta stage with selected global pharma partners to a commercial launch in the Nordics in the second half of 2026.
Founded in 2022 and headquartered in Lund, Sweden, TrackPaw Scientific is on a mission to address one of the key reasons behind over 90% of failures in clinical development: subjective and inconsistent conclusions from animal-based preclinical studies. By combining machine learning and sensor technology to monitor animal behaviour and weight in real time, the company provides scientists with objective, high-resolution data across a wide range of disease areas. This leads to more robust study outcomes, improved animal welfare, and faster access to effective new medicines.
‘’The team and board are truly honoured to have such prominent investors backing us and our mission. The investment truly symbolizes an unmet need in the market that we have a solution for. We’re now ready to emerge from stealth mode and work towards satisfying the hungry preclinical and breeding market with 24/7 cutting-edge insights.’’ comments CEO and Co-founder Liza T. Albrektson.
With this capital injection, TrackPaw Scientific will be able to accelerate the work to commercial launch readiness in the Nordics during the second half of 2026, launching a new and groundbreaking solution for digital monitoring and analysis in preclinical research.
“We believe TrackPaw has assembled an outstanding team and a truly remarkable product that stands to transform the landscape of preclinical research. By delivering more reliable and sustainable data, they not only enhance the quality of scientific outcomes but also drive significant cost savings for major pharma players. This isn’t just an exciting initiative, it’s a game changer that sets a new standard for the industry and elevates animal welfare to new heights.” Says Alexander Jöndell, Partner at Fåhraeus Startup & Growth.
"We’re excited to back TrackPaw as they tackle one of the biggest bottlenecks in preclinical research. Their innovative approach has the potential to improve data quality, accelerate drug development, and raise animal welfare standards – all of which are critical for the future of life science" comments Jonas Jendi, Senior Investment Director at Industrifonden.
The global preclinical research market is estimated to reach over 11 BEUR by 2030, driven by increasing demand for faster and more reliable drug discovery. TrackPaw’s platform is uniquely positioned to set a new standard in this space by delivering a scalable solution for all cages inside animal facilities. With a team combining expertise in algorithm development, product engineering and animal science, TrackPaw Scientific aims to become the leading provider of insights in early drug development, covering 6% of the global market by 2030.